Synageva BioPharma (GEVA)

[surf1944]

Trimeris Reports Second Quarter 2008 FUZEON(R) Sales Results
Monday July 21, 9:00 am ET

DURHAM, N.C.--(BUSINESS WIRE)--Trimeris, Inc. (NASDAQ:TRMS - News) today announced worldwide net sales of FUZEON for the second quarter of 2008 were $38.3 million, down 38 percent from $62.0 million in the second quarter of 2007. Net sales of FUZEON in the U.S. and Canada for the second quarter of 2008 were $16.1 million, down 51 percent from $32.9 million in the second quarter of 2007. Net sales of FUZEON outside the U.S. and Canada for the second quarter of 2008 were $22.2 million, down 24 percent from $29.2 million in the second quarter of 2007. All sales of FUZEON are recorded by F. Hoffmann-La Roche Ltd, ("Roche"), Trimeris' collaborative partner.

Net sales of FUZEON for the first half of 2008 were $81.0 million, a decrease of 36 percent from $126.3 million in the first half of 2007. Net sales of FUZEON in the U.S. and Canada for the first half of 2008 were $33.1 million, a decrease of 47 percent from $62.2 million in the first half of 2007. Net sales of FUZEON outside the U.S. and Canada for the first half of 2008 were $47.9 million, a decrease of 25 percent from $64.1 million in the first half of 2007.

The release of complete financial results for the second quarter of 2008 will take place in early August 2008.

Net Fuzeon Sales

The table below presents net FUZEON sales by quarter beginning in the first quarter of 2006:

(millions)


2008
Q1 Q2 Q3 Q4 Total
U.S/Canada Net Sales $ 17.0 $ 16.1 - - $ 33.1
Ex. U.S/Canada Net Sales 25.7 22.2 - - 47.9
Global Net Sales $ 42.7 $ 38.3 - - $ 81.0
Brazil Purchase - - - - -

2007
Q1 Q2 Q3 Q4 Total
U.S/Canada Net Sales $ 29.3 $ 32.9 $ 30.6 $ 31.5 $ 124.3
Ex. U.S/Canada Net Sales 35.0 29.2 43.3 35.0 142.5
Global Net Sales $ 64.3 $ 62.0 $ 73.9 $ 66.5 $ 266.8
Brazil Purchase $ 6.0 - $ 13.8 $ 7.3 $ 27.1

2006
Q1 Q2 Q3 Q4 Total
U.S/Canada Net Sales $ 27.4 $ 31.1 $ 33.5 $ 42.2 $ 134.2
Ex. U.S/Canada Net Sales 28.0 26.2 29.5 31.1 114.8
Global Net Sales $ 55.4 $ 57.2 $ 63.0 $ 73.3 $ 249.0
Brazil Purchase $ 5.3 - $ 4.4 $ 4.7 $ 14.3

(numbers may not add due to rounding)

About Trimeris, Inc.

Trimeris, Inc. (NASDAQ:TRMS - News) is a biopharmaceutical company engaged in the development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about Trimeris, please visit the Company's website at http://www.trimeris.com.